Cargando…

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18–30), and high-risk (≥31) categories. Our pi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Molly E, Dabbs, David J, Shuai, Yongli, Brufsky, Adam M, Jankowitz, Rachel, Puhalla, Shannon L, Bhargava, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647116/ https://www.ncbi.nlm.nih.gov/pubmed/23503643 http://dx.doi.org/10.1038/modpathol.2013.36

Ejemplares similares

Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study
por: Bhargava, Rohit, et al.
Publicado: (2019)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
por: Li, Hongxiao, et al.
Publicado: (2022)

The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
por: Bhargava, Rohit, et al.
Publicado: (2020)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
por: Zarella, Mark D., et al.
Publicado: (2018)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
por: Ozmen, Vahit, et al.
Publicado: (2016)

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
por: Zhang, Michelle, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
por: Berdunov, Vladislav, et al.
Publicado: (2022)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
por: Zhu, Xiaofu, et al.
Publicado: (2021)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
por: Iles, Kathleen, et al.
Publicado: (2022)

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
por: Choi, Joseph Do Woong, et al.
Publicado: (2022)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

Is radiomic MRI a feasible alternative to OncotypeDX(®) recurrence score testing? A systematic review and meta-analysis
por: Davey, M G, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_krovqo739m1h3uscr3gstvf849